A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals live attenuated measles-mumps-rubella-varicella vaccine and Baxter's Neisseria meningitidis C conjugate vaccine versus separate administration of each of the vaccines in healthy children aged 12 through 23 months.

Trial Profile

A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals live attenuated measles-mumps-rubella-varicella vaccine and Baxter's Neisseria meningitidis C conjugate vaccine versus separate administration of each of the vaccines in healthy children aged 12 through 23 months.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2012

At a glance

  • Drugs Meningococcal vaccine group C conjugate; MMR-varicella zoster virus vaccine
  • Indications Chickenpox; Measles; Meningococcal group C infections; Mumps; Neisseria infections; Rubella; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline Biologicals
  • Most Recent Events

    • 06 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top